Whole-Body Hyperthermia (WBH) as a Rapid-Acting Antidepressant for Major Depressive Disorder (MDD)
Whole-Body Hyperthermia (WBH) as a Rapid-Acting Antidepressant for Major Depressive Disorder (MDD)
Published: 2025-10-14 | Last Reviewed: 2025-10-14
1. Whole-Body Hyperthermia (WBH): A Single Session for Rapid Antidepressant Effects
The *Whole-Body Hyperthermia (WBH) treatment* has been validated as a *rapid-acting antidepressant* for patients with *Major Depressive Disorder (MDD)* [1]. A randomized clinical trial demonstrated that a *single session of WBH* can produce a significant and sustained *reduction in depressive symptoms* for several weeks. This non-pharmacological approach works by safely elevating the core body temperature to fever-range levels, triggering neurobiological and physiological responses beneficial for mood regulation.
Key Findings from the Randomized Clinical Trial
The landmark RCT (Janssen et al., 2016) comparing WBH with a sham control procedure provided strong evidence for its efficacy:
- *Sustained Symptom Reduction:* Patients who received the WBH treatment showed a statistically significant and lasting *reduction in depressive symptoms* compared to the control group.
- *Rapid Onset:* The treatment is characterized by its *rapid onset of action*, distinguishing it from traditional antidepressants that typically require several weeks to reach efficacy.
- *Mechanism Hypothesis:* The rapid effect is hypothesized to be linked to WBH’s ability to activate the hypothalamic-pituitary-adrenal (HPA) axis, modulate *neurotransmitters*, and induce the systemic release of heat shock proteins and anti-inflammatory cytokines, pathways often dysregulated in MDD.
2. WBH’s Role in Psychiatry and Neurobiological Mechanisms
The study places WBH within the emerging field of treatments that target the *body-brain axis* for mood disorders.
- *Non-Pharmacological Approach:* WBH offers a valuable *non-pharmacological option* for MDD patients, particularly those who may be resistant to or intolerant of conventional drug treatments.
- *Biological Foundation:* The efficacy of WBH supports the *”thermal hypothesis”* of depression, which suggests that deficits in thermoregulation and certain inflammatory markers contribute to depressive episodes. WBH temporarily resets these biological processes.
- *Single-Session Treatment:* The finding that profound antidepressant benefits can result from a *single session* is a crucial element that distinguishes WBH from most other established MDD therapies.
Frequently Asked Questions (FAQ) about WBH and Depression
Is Whole-Body Hyperthermia (WBH) effective for Major Depressive Disorder?
Yes. A *Randomized Clinical Trial (2016)* demonstrated that a *single session of WBH* acts as a *rapid-acting antidepressant*, significantly reducing depressive symptoms in patients with MDD [1].
How quickly does WBH work to relieve depression symptoms?
WBH is notable for its *rapid onset of action*. Antidepressant benefits are often noticeable soon after the single session, differentiating it from traditional oral medications that require weeks to take effect.
How can the von Ardenne Iratherm 1000 Whole-Body Hyperthermia wIRA device be used for fibromyalgia?
Overview of recommended WBH sessions with von Ardenne Iratherm 1000 WBH wIRA device and target temperatures – Treatments shall only be performed after final consultation with a medical doctor
| Indication | No. of sessions | Target temperature | Therapy time Increase phase Plateau phase | Rest time Resting phase | Total WBH session time | |
| Major Depressive Disorder | 1+ | 38.5 °C | 105 -170 min | 30 min | ~ 2-3 hours | |
| 45-110 min | 60 min | |||||
Can Whole-Body Hyperthermia with wIRA be used for other pathologies?
Yes. Other benefits and areas of application of Whole Body Hyperthermia include Oncology, accelerated metabolism , stimulation of the hormonal system , reduction in muscle tone , enhanced nerve conduction, Systemic sclerosis, Depressive episode, Essential (primary) hypertension, Dorsalgia, Fibromyalgia, Ankylosing spondylitis
A more detailed list of studies and effects ( (from foundational studies on wIRA technology to crucial Phase III clinical trials) can be found here
Scientific References (E-E-A-T)
- Janssen C.W., Lowry C.A., Mehl M.R., Allen J.J.B., Kelly K.L., Gartner D.E., Medrano A., Begay T.K., Rentscher K., White J.J., Fridman A., Roberts L.J., Robbins M.L., Hanusch K.U., Cole S.P., Raison C.L. Whole-Body Hyperthermia for the Treatment of Major Depressive Disorder – A Randomized Clinical Trial. JAMA Psychiatry. May 12, 2016. doi:10.1001/jamapsychiatry.2016.1031


